The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...

Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for ...

Detailed price information for Nurix Therapeutics Inc (NRIX-Q) from The Globe and Mail including charting and trades.

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the ...

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

Furthermore, a near-doubling of 12-month survival was also achieved with the elraglusib regimen vs GnP alone (44.4% vs 22.3%), and at 24 months, the survival rate was nearly 5 times higher in the ...

A toxin secreted by cholera bacteria can inhibit the growth of colorectal cancer without causing any measurable damage to the ...

A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor ...

A long-standing practice through which people hospitalized for blood cancer treatment are restricted to eating cooked foods ...